Event in Progress:
Research Tree provides access to ongoing research coverage, media content and regulatory news on Vitrolife Ab. We currently have 1 research reports from 0 professional analysts.
Companies: Totally Plc
Canaccord Genuity
ReNeuron has announced its H124 results (to end-September 2023), reaffirming its commitment to advance CustomEx (TM), its proprietary stem cell-derived exosome delivery platform. The key operational update from the period included in vivo data, marking a crucial step towards validating CustomEx (TM) and distinguishing it from peers in the exosome delivery space due to its cellular and tissue-targeting capabilities. As of 30 September 2023, ReNeuron had a cash balance of £5.1m, which we estimate
Companies: ReNeuron Group plc
Edison
Cambridge Nutritional Sciences (CNS) has published its H1 2024 results to end September 2023. Group revenues grew 44% to £4.9m and gross profits increased by 63% to £3.1m, with the company benefitting from newfound operational efficiencies. With its now streamlined strategy focussing on the core Health & Nutrition business and the initial signs of an encouraging uptick in sales momentum, we believe the company is well positioned for growth that will help create future value for shareholders. We
Companies: Cambridge Nutritional Sciences PLC
Cavendish
Creo Medical has announced that its EU notified body has guided for an accelerated clinical pathway for its Speedboat UltraSlim device, the slimmest Speedboat Inject version that is compatible with most endoscopes. The reduced regulatory path will enable the company to launch the versatile product in Europe in early 2024, roughly 18 months earlier than planned. As the FDA application was submitted for this device in February 2023 (management expects clearance in Q423), UltraSlim is now projected
Companies: Creo Medical Group Plc
TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics and dental markets. 1H’23 results highlighted the benefits and efficiencies being derived from investment and reorganisation in manufacturing capacity, with the first underlying EBITDA-positive reporting period. With further strong growth forecast
Companies: Tissue Regenix Group plc (TRX:LON)Tissue Regenix Group plc (TRX:LON)
Hardman & Co
Companies: MRL BBSN POLB
FY22 was a key inflection period for Creo with significant traction in the adoption of Speedboat Inject (its flagship electrosurgical device) and its proprietary CROMA technology platform, reflected in major robotic deals with Intuitive Surgical and CMR Surgical. Total revenue growth (8% y-o-y to £27.2m) was in line with consensus (£27m) and was primarily driven by Creo’s core technology business. Operating losses rose to £30.8m, affected by increased personnel and R&D expenses, although managem
In a well-attended Capital Markets Day on Nov 7, Creo made no new announcements but showed qualitatively how the next few years are likely to evolve with insights from three enthusiastic medical users. We took on board three important qualitative observations from the event.Firstly, the importance
Proactive
Feature article: Macro issues dominate investor sentiment - Some basics for investors The big topics in the investment world at the moment seem to be macroeconomic. With that in mind, we thought it would be useful to revisit some of the basics of the terms being used in the current environment, and to remind investors of the things to look out for (indeed, many younger investors may not have come across some of these influences in their investing lifetime): • Recession does not affect
Companies: OCI ICGT FAS FJV IBT APP ARBB RECI PANR TRX FCSS AVO DNL FEV FSV STX VTA E7F0
Companies: CNSL HEIQ JOG
Avon Protection should be well positioned to recover strongly following the value destruction caused by the relatively small Armor activity, which now faces a managed closure over the next two years. Future growth rates are diminished by the exit but remain healthy in the further focused core of Respiratory and Head Protection. Management needs to restore investor confidence as it continues with its growth strategy, in order to regain the historical premium rating to its UK defence peers. In thi
Companies: Avon Protection PLC
Companies: Oxford BioDynamics PLC
Shore Capital
Companies: PCIP TIME DEC BOOM GELN POLB
Record waiting times and backlogs of elective care procedures are both caused by a structural lack of capacity within the NHS, that was exacerbated by the pandemic. Totally is one of the only UK-quoted providers of independent healthcare services that has the scale and breadth to help address this and has been growing rapidly in recent years. Whilst procurement delays and inflationary pressures have impacted in the short term, the recent pullback in the shares looks overdone and has, in our opin
Singer Capital Markets
Companies: Warpaint London PLC
Share: